This trial is evaluating whether CUDC-907 will improve 1 primary outcome and 6 secondary outcomes in patients with Lymphoma. Measurement will happen over the course of 2 months.
This trial requires 44 total participants across 2 different treatment groups
This trial involves 2 different treatments. CUDC-907 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
In lymphoma, treatment varies depending on the type of cancer, how dangerous it is, whether the cancer is in lymph nodes near the skin, and the extent of the disease. Most cases of lymphoma were treated with radiation therapy with some combination of other techniques. Most cases of lymphoma are treatable, but only half of lymphoma cases can be cured.
In order to implement more effective and sustained surveillance programs for this population, accurate numbers on the size and impact of lymphomas are needed in the United States. According to the estimates obtained in this investigation, around 10,000 to 18,000 new cases can be diagnosed yearly in the United States. However, the number of lymphoma deaths exceeds that by a four-to-one margin (about 43,000 to 97,000), with only 730 to 1,200 physicians practicing in the country. This suggests the need for more awareness and better medical education of physicians and other medical personnel about lymphoma.
Lymphoma is a cancer that forms mainly in the lymphatic system and spreads to other parts of the body. While about 20 million people will be affected by the disease, only a few millions of people actually develop a tumor. Primary lymphomas are more common in early adulthood, women, and Caucasians. Histologically, the most common form is non-Hodgkin's lymphoma, and it has an excellent prognosis. The cancer is diagnosed by a lymph node biopsy as a disease that is treated by chemotherapy and radiotherapy.
The most common signs of lymphoma are enlarged lymph nodes (75%), fever (43%), weight loss (44%), cough (39%), night sweats (36%), skin changes (33%), chest pain (33%), headache (33%), and loss of lean mass (21%). For lymphoproliferative disorders, swollen lymph nodes (89%), skin rash (48%), swollen lymph nodes (43%), night sweats (40%), fever (38%), and weight loss (29%) are the most common signs, whereas lymphoma with B immunophenotype presents with anemia, anorexia, and fever (38%), enlarged lymph nodes (38%), and night sweats (38%).
Lymphoma has a very poor outlook. The overall five year survival rate can be as low as 16% in the case of marginal zone B-cell lymphoma and even less in other types of lymphoma like mantle cell lymphoma, which is an extremely refractory cancer.
Findings from a recent study, cudc-907 treatment led to clinical improvements and long term tumor control in both treatment naïve and pretreated patients with newly diagnosed and/or relapsing disease. In fact, the combination of cudc-907 with rituximab resulted in higher rates of CR compared to either agent alone and resulted in longer PFS. Future studies in combination and single agents are ongoing to better characterize the role of cudc-907 in treating DLBCL.
A majority of individuals with lymphoma report that their diagnosis was not the result of one problem with their health but rather multiple unhealthy behaviors. The most common causes for development of lymphoma were the behaviors of smoking or marijuana use and obesity. There is a need to address the multiple unhealthy behaviors of smoking, marijuana use, and obesity in order to prevent the development of a lymphoma and to facilitate the treatment of individuals with lymphoma.
Cudc-907 could be the next successful anticancer drug for treating certain types of acute myeloid leukaemia. As a protein tyrosine kinase (PTK), Cudc-907 directly inhibits T-cell leukaemia protein (TCL-1) and BCR/ABL kinase (BCR) enzymes and in the same time reverses several abnormal kinase activities of TCL-1 and BCR. Therefore, Cudc-907 has a unique and selective anti-kinase and selective antiproliferative profile. This leads to improved TCL-1 and BCR protein levels and decreased the proliferation of T-cell leukaemia.
Lymphoma was a significant disease in all four countries, with the USA, Canada and the UK having the most. Although the overall incidence is decreasing, lymphoma remains one of the most significant diseases treated in Western countries.
The addition of Cudc-907 to standard chemotherapy had no effect on progression-free or overall survival. Patients who had cudc-907 had a trend toward higher overall response rates than did patients who received the placebo. The drug was well tolerated.